Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
- PMID: 22982675
- DOI: 10.1016/j.bbrc.2012.08.133
Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
Abstract
Withaferin A, the active component of Withania somnifera, causes cytotoxicity in a variety of tumor cell lines. In this study, we show that withaferin A inhibits constitutive and IL-6-induced phosphorylation of STAT3 (on Tyr705), but not IFN-γ-induced STAT1 phosphorylation. Withaferin A-induced down-regulation of STAT3 activation is associated with a reduction in Janus-activated kinase 2 (JAK2) activity. Withaferin A also down-regulates the expression of STAT3 regulated genes such as Bcl-xL, Bcl-2, cyclin D1 and survivin. The apoptotic effect of withaferin A in Caki human renal cancer cells was investigated. Withaferin A induced dose-dependent apoptotic cell death in Caki cells, as measured by FACS analysis and PARP cleavage. Furthermore, overexpression of STAT3 attenuated withaferin A-induced apoptosis. Taken together, the present study provides strong evidence that down-regulation of the STAT3 signaling pathway mediates withaferin A-induced apoptosis.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.Clin Cancer Res. 2006 Nov 15;12(22):6844-52. doi: 10.1158/1078-0432.CCR-06-1330. Clin Cancer Res. 2006. PMID: 17121906
-
Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells.J Pharmacol Exp Ther. 2010 Jul;334(1):285-93. doi: 10.1124/jpet.110.165498. Epub 2010 Apr 8. J Pharmacol Exp Ther. 2010. PMID: 20378717
-
Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells.Int Immunopharmacol. 2011 Aug;11(8):1137-42. doi: 10.1016/j.intimp.2011.02.029. Epub 2011 Mar 21. Int Immunopharmacol. 2011. PMID: 21396905
-
Withaferin A and its potential role in glioblastoma (GBM).J Neurooncol. 2017 Jan;131(2):201-211. doi: 10.1007/s11060-016-2303-x. Epub 2016 Nov 11. J Neurooncol. 2017. PMID: 27837436 Review.
-
The Therapeutic Effects of Withaferin A against Cancer: Overview and Updates.Curr Mol Med. 2024;24(4):404-418. doi: 10.2174/1566524023666230418094708. Curr Mol Med. 2024. PMID: 37076466 Review.
Cited by
-
Research for understanding as opposed to evaluating Ayurveda.Anc Sci Life. 2014 Oct-Dec;34(2):61-3. doi: 10.4103/0257-7941.153456. Anc Sci Life. 2014. PMID: 25861137 Free PMC article. No abstract available.
-
Molecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling.Cancers (Basel). 2024 Sep 5;16(17):3090. doi: 10.3390/cancers16173090. Cancers (Basel). 2024. PMID: 39272948 Free PMC article.
-
Withaferin A Inhibits Nuclear Factor-κB-Dependent Pro-Inflammatory and Stress Response Pathways in the Astrocytes.Neural Plast. 2015;2015:381964. doi: 10.1155/2015/381964. Epub 2015 Jul 21. Neural Plast. 2015. PMID: 26266054 Free PMC article.
-
Lycorine exerts antitumor activity against osteosarcoma cells in vitro and in vivo xenograft model through the JAK2/STAT3 pathway.Onco Targets Ther. 2019 Jul 8;12:5377-5388. doi: 10.2147/OTT.S202026. eCollection 2019. Onco Targets Ther. 2019. PMID: 31371981 Free PMC article.
-
Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A.J Adv Res. 2021 Jun 11;34:79-91. doi: 10.1016/j.jare.2021.06.004. eCollection 2021 Dec. J Adv Res. 2021. PMID: 35024182 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
